With New Strategy, Alnylam Again Shuffles Its Pipeline | GenomeWeb

This article has been updated to clarify Alnylam's partnership with Medtronic and statements regarding its liver cancer program.

By Doug Macron

When Alnylam Pharmaceuticals announced last week its latest product-development strategy, it said it reflected a shift of its focus onto "genetically defined diseases" offering the potential for "early commercialization opportunities."

It also marked the latest in a series of pipeline changeups the company has undertaken since it was founded in 2002.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.